AstraZeneca's Tagrisso, or osimertinib, has been tagged for accelerated review after receiving breakthrough therapy status from the FDA. The drug is an adjuvant treatment for patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer who have undergone complete tumor resection.
AZ's osimertinib gains breakthrough therapy tag
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.